108 related articles for article (PubMed ID: 17094579)
1. [Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma].
Tsujimura A; Miyamura K; Kuwatsuka Y; Inamoto Y; Tokunaga M; Oba T; Terakura S; Suzuki R; Ito M; Murase T; Kodera Y
Rinsho Ketsueki; 2006 Oct; 47(10):1387-92. PubMed ID: 17094579
[TBL] [Abstract][Full Text] [Related]
2. [A case of pulmonary intravascular lymphoma treated with CHOP chemotherapy plus rituximab].
Ohkubo H; Yoshida T; Ohta K; Takaku T; Katagiri T; Paku J; Kasuga I; Minemura K; Gotoh A; Serizawa H; Mukai K; Ohyashiki K
Gan To Kagaku Ryoho; 2005 Apr; 32(4):553-6. PubMed ID: 15853227
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Oki Y; Ogura M; Kato H; Kikuchi A; Taji H; Kagami Y; Oshiro A; Tsujimura A; Yamamoto K; Morishima Y
Cancer Sci; 2008 Jan; 99(1):179-84. PubMed ID: 17991293
[TBL] [Abstract][Full Text] [Related]
4. [Intravascular lymphoma confirmed by brain biopsy, quickly treated by chemotherapy: a case report].
Inoue D; Hamamura T; Uehara T; Miyoshi K; Katsuragi T; Takeshita I; Hamada T
No Shinkei Geka; 2009 Apr; 37(4):369-74. PubMed ID: 19364028
[TBL] [Abstract][Full Text] [Related]
5. [Dramatic but temporary improvements in a case of CNS intravascular malignant lymphomatosis].
Aoyama M; Aoki T; Matsuura Y; Yamanoi T; Watanabe A; Saitou N; Honma M; Ishikawa T; Kodama N; Yamamoto T
Rinsho Shinkeigaku; 2003; 43(1-2):6-11. PubMed ID: 12820543
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
7. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
8. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
10. [Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy].
Tadokoro J; Arai Y; Tokita K; Iso H; Nakamura Y; Maki K; Sasaki K; Mitani K
Rinsho Ketsueki; 2007 Jan; 48(1):61-3. PubMed ID: 17313078
[TBL] [Abstract][Full Text] [Related]
11. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
Sumi M; Ichikawa N; Shimizu I; Yotsumoto M; Ueno M; Kobayashi H
Rinsho Ketsueki; 2007 Jul; 48(7):571-5. PubMed ID: 17695307
[TBL] [Abstract][Full Text] [Related]
12. [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive].
Ohshima R; Tomita N; Motohashi K; Ieda A; Hyou R; Fujisawa S; Fujita H; Sakai R; Koharazawa H; Kuwabara H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2005 Jun; 46(6):453-7. PubMed ID: 16447727
[TBL] [Abstract][Full Text] [Related]
13. [Splenic marginal zone B-cell lymphoma with bilateral renal invasion after splenectomy].
Hoshino T; Iriuchijima H; Ogawa Y; Irisawa H; Jinbo T
Rinsho Ketsueki; 2008 Jan; 49(1):35-9. PubMed ID: 18277594
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
17. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
18. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
